Poster Topic

(1-001) Standardizing the Assessment of Clinical Trial Complexity for Improved Pharmacy Resource Management

(1-002) Establishing a Diabetes Self-management Training Program Within the Pharmacy Chronic Care Clinic

(1-003) Modernization of an Acute Care Productivity Model for Clinical Pharmacy Practitioners at Veteran Health Indiana

(1-004) Implementation of a Standardized System for Reverse Distribution of Medications

(1-005) Optimizing Third-Party Reimbursement for Pharmacy Revenue

(2-025) Evaluating Paliperidone Dosage Forms Using Multi-Criteria Decision Analysis: An Assessment of Clinical, Economic, and Stakeholder Priorities

(2-311) From MILT to CNR: A Systems-Level Evaluation of NDC Tracking and Financial Outcomes

(2-374) Evaluating Dose Rounding in an Infusion Pharmacy for Chemotherapy Drugs to Optimize Pharmacy Savings

(3-175) Impact of Task Redistribution on Pharmacist Productivity in Clinical Review at a Health-System Outpatient Pharmacy

(3-220) Standardized Manufacturer-Controlled Doses to Reduce Controlled Substance Waste and Variances at an Academic Medical Center

(3-280) Drug Shortage Management: A Collaborative, Team-Based Approach

(3-341) Projecting Generic Drug Cost Increases from Section 301 Tariffs in Workers’ Compensation

(4-001) Creation of a Cost of Goods Sold Report to Influence Medication Fiscal Accountability in an Academic Medical Center

(4-002) Implementation and Early Impact of a Pharmacy Operations and Compliance Council in an Acute Care Academic Medical Center

(4-003) Biosimilar Adoption Across Hospital Cohort and Associated Cost Savings

(4-004) Addressing the Pharmacy Leadership Gap: A Values-Based Pharmacy Leadership Readiness Program

(4-005) GROW-ing Frontline Pharmacy Staff QI Involvement

(4-006) Evaluating Outsourced vs. In-House Compounded Infusion Bags: A Multi-Hospital Comparative Analysis

(4-007) Improving Rural Hospital Denial Write-Offs for Chemotherapy Medications by Developing a Multi-Layer Prior Authorization Process

(5-138) National Survey of Pharmacy Faculty to Determine Time Spent in Preparation of Course Materials

(5-265) Understanding Treatment Patterns in Substance Use Disorders and Assessing the Economic Burden of Opioid-Associated Inpatient Admissions in New York.

(5-310) Assessing the Adoption of Novel Therapies in a Private/Public Payer System: A Study in Fitusiran, Sebetralstat, and Nipocalimab

(6-062) Utilization of IVIG Inpatient at a Large Academic Medical Center

(6-129) Improving Oxycodone Oversight Through Use of Omnicell™ and ControlCheck™

(6-141) Improving the Medication Receiving Process in an Inpatient Pharmacy to Support Financial Stewardship Through Timely and Accurate Invoice Processing

(6-256) Analyzing Reasons for Pennsylvania Pharmacy Closures in 2024

(7-030) Management of a Manual Dispense Workflow During Automated Medication Dispensing Carousel Downtime

(7-155) Workflow and Productivity Optimization: A Direct Time-Study

(7-220) Waste Reduction of Patient Controlled Analgesia Medications in a Community Hospital Setting

(7-254) Pyxis Optimization in a Rehabilitation Hospital Setting

(7-322) Developing a List of Vital, Essential, and Desirable Drugs for Proactive Drug Shortage Management

(8-001) Assessing a National GPO’s Sourcing Evaluation of Supply Reliability: A Retrospective Review of Product Backorder Incidence

(8-002) Evaluating the Effect of a Global Holiday Calendar on Faculty Scheduling

(8-003) Pharmacy-Led Strategies to Advance Diversity in Sickle Cell Disease Clinical Trials: A Policy and Practice Literature Review

(8-004) Medication Use Management: Collaborative Strategies for Sustainable Cost Containment, Quality, and Safety in Patient Care

(8-005) Predicting Sterile Compounding Workload

(8-006) Implementation of a Collaborative Sugammadex Dosing and Aliquot Procurement Practice Model to Generate Value Add for Cost Reduction

(8-007) Pharmacy Policy Harmonization Across a Small Hospital System

(8-008) Decreasing Wasted Pharmacy Technician Time by Reducing Batching of Tasks to Fill Automated Dispensing Cabinets

(9-136) Implementation of a Pharmacy-Compounded Alteplase 1mg/2mL for Central Venous Catheter Occlusions to Cost Saving Initiative

(9-271) Evaluation of AI Generated HCAPHS Data for Pharmacy Enhancement of Patient Experience in a Large Academic Health System

(9-287) Utilization of Business Intelligence Software to Conduct a Therapeutic Class Review of Solid Organ Transplant Medications

(9-288) Leveraging Business Intelligence Software for a Hematopoietic Agent Therapeutic Class Review

(9-353) Operating Room Optimization for 340B Maximization & WAC Reduction

(9-430) Evaluation of a Dynamic System List Tool to Optimize Patient Care Prioritization

(9-449) Evaluating Patient Adherence and Economic Outcomes of a University-Affiliated Pharmacy Call Center Intervention

(9-471) Strategic Evaluation of Meds2Beds: Implications for Contract Renewal and Enterprise Growth at BayCare

(10-006) From Stabilization to Silencing: Assessing Adherence and Outcomes of Tafamidis and Vutrisiran in Patients with Cardiac Amyloidosis in a Rural Setting

(10-082) Evaluating the impact of weekend and “after hours” inpatient chemotherapy initiation to optimize pharmacy workflow

(10-100) Assessing the Impact of the Medicare Prescription Payment Plan on Patient Adherence of Chronic Medications

(10-163) Evaluating Pharmacy Policies and Effectiveness by Way of Pharmacist Peer Review Over a Specific Time Frame

(10-250) Beyond Clinical Outcomes: The Operational and Financial Benefits of Insulin Lispro in Hyperkalemia Protocols

(10-324) Androgen Deprivation Therapy for Advanced Prostate Cancer Treatment: An Academic Detailing Approach to Optimize Medication Utilization

(10-389) Integration and Optimization of a Health-System Medication Access Team: Centralizing Workflows and Building Scalable Infrastructure

(10-407) 340B Optimization and Compliance using a TPA at a DSH

(11-063) Impact of Omalizumab Syringe-to-Vial Formulary Transition at a Hospital-Based Infusion Clinic

(11-091) Assessing Implementation of Pharmacy Intern Provisional Order Verification

(11-151) Review of Insulin Pen Dispenses in a 240 Bed Community Hospital

(11-164) Utilizing a Multidisciplinary Approach to Increase Post-surgical Medication Access through Meds to Beds

(11-165) Optimizing Rebates on a Self-Insured Pharmacy Benefit Plan

(11-202) Cost Analysis of Intravenous Push versus Intermittent Infusion Administration of Daptomycin, Lacosamide, Levetiracetam, and Ertapenem in Adult Inpatients

(11-292) Impact of a Prescription Assistance Plan on Readmission Rates Following COPD Exacerbations

(12-029) Intravenous Immunoglobulin Administration Efficiency: Effects of Scanning Compliance and Incomplete Infusions on Charge Capture

(12-067) Assessment of Expenses Associated with Non-Formulary Inpatient Chemotherapy Administration in Novant Health Acute Care Facilities

(12-119) Infusion Fusion: Where Pharmacist Interventions Meets Operational Success: A Study Aimed at Optimizing Operational Workflow in a Non-Oncology Infusion Center

(12-236) Pharmacist-Provider Collaborative Clinic for Intravenous Iron Management in Iron Deficiency Anemia

(12-270) Evaluation of overridden medications removed from automated dispensing cabinets within a large academic medical center

(12-320) Evaluation of Intravenous Versus Oral Acetaminophen Prescribing and Costs in Acute Care

(12-367) From policy to practice: empowering colleagues through Pharmacy & Therapeutics committee engagement

(13-021) Standardizing Biologics Management: A Community Health System Approach to Formulary Development and Implementation

(13-031) Impact of a Newly Implemented Enterprise-Wide Formulary Strategy in Outpatient Physician Clinics

(13-038) Class of trade: an exploratory review through the lens of a large group purchasing organization

(13-168) Descriptive Analysis of Harris Health’s Lyndon B. Johnson (LBJ) and Ben Taub (BT) Emergency Care Medication History Process

(13-181) Understanding the Behavioral Drivers of Overstocking Medications in Health-System Pharmacies: A Qualitative Study

(13-207) Optimizing Albumin Dosing After Large-Volume Paracentesis: Are Doses Consistently Ordered or Is an Order Set Needed? MUE Proposal

(13-283) Optimizing 340B Accumulations for Medications Used in Anesthesiology Procedures

(13-323) Budget Impact Analysis of Inpatient Transitions of Care Team Interventions at Providence St. Peter Hospital

(13-393) Evaluating Cost and Efficacy After Developing and Implementing Criteria-for-Use for Rifaximin Across a Multi-Hospital Healthcare System

(1-006) Evaluation of Inhaled Corticosteroid Prescribing for Patients with COPD within the Central Alabama Veterans Health Care System

(1-007) Adherence to Recommended Vaccinations in a Veteran Rheumatology Population: A Quality Improvement Initiative

(1-008) Evaluating Pharmacist Impact in Hepatitis C Treatment and Barriers to Treatment Completion: A Quality Improvement Initiative within the Nuka System of Care

(1-009) Safety and efficacy of GLP-1 weight loss medications in the VA for patients 75 years and older

(1-010) Evaluation of Gout Outcomes among Veterans Prescribed Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

(1-011) Impact of GLP-1 Receptor Agonists on PHQ-9 scores in Patients with Major Depressive Disorder with a Comorbidity of Type 2 Diabetes Mellitus or Obesity

(1-012) Prevalence of Veterans at risk for overbasalization and utilization of newer treatment options at a single Department of Veterans Affairs Medical Center

(1-013) Evaluation of Cardiovascular Medication Use in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) at VA Greater Los Angeles

(1-014) Piloting a Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2i) Dashboard to Improve Diabetes and Renal Outcomes

(1-015) Impact of Continuous Glucose Monitoring (CGM) on HbA1c at Veterans Affairs Central California Health Care System (VACCHCS) Primary Care Clinic

(1-016) Comparison of Mixed Hyperlipidemia Management for Veterans Enrolled in a Specialty Pharmacist-Managed Lipid Clinic versus Usual Care

(1-017) Pharmacist Involvement and Weight-loss Outcomes in Veterans Prescribed Anti-Obesity Medications at the VA Eastern Colorado Healthcare System

(1-018) Evaluation of Dopamine Agonists Used for Restless Legs Syndrome at the VA Connecticut Healthcare System

(1-019) Progression of Diabetic Retinopathy in Patients with Rapid A1c Lowering Using Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

(1-020) Improving Acceptance of Naloxone in Veterans with Opioid Use Disorder Utilizing a Veteran-to-Veteran Approach

(1-021) GLP-1 Agonist Based Weight Loss Medication Renewal Criteria Evaluation at the Miami Veterans Affairs Healthcare System

(1-022) Evaluating and Improving the Prescribing of Guideline-Directed Medication Therapy for Chronic Obstructive Pulmonary Disease (COPD) at the James A. Haley Veterans Hospital & Clinics

(1-023) Increasing SGLT2 Inhibitor Utilization in Patients with Type 2 Diabetes and Concurrent ASCVD or HF or CKD

(1-024) Pharmacist-Driven Optimization of Sodium-Glucose Cotransporter-2 Inhibitor Therapy While Mitigating Sulfonylurea-Associated Risks in Veterans

(1-025) Evaluating Initiation of Continuous Glucose Monitors Impact on Hemoglobin A1c In Veterans with Type 2 Diabetes in Pharmacist-Led Clinics at the Miami VA Healthcare System

(1-026) Impact of an Updated Chronic Obstructive Pulmonary Disease (COPD) Order Set and Provider Education on COPD Dashboard Metrics

(1-027) Primary Care Pharmacist-Led Initiative to Improve Bone Health and Reduce Fracture Risk in Patients with Type 2 Diabetes at Two Veterans Affairs (VA) Locations

(1-028) Deprescribing Inappropriate Sedative-Hypnotics in Older Adults at the Boise VA Medical Center (VAMC)

(1-029) Implementation of an Oncology-Primary Care Coordination Process to Manage Hyperglycemia Risk in Patients with Type 2 Diabetes and Prediabetes Across Two Veterans Affairs (VA) Locations

(1-030) Switching Patients With Obesity From Semaglutide to Tirzepatide Due to Adverse Effects

(1-031) Assessing the Impact of a Pharmacist-Led Weight Loss Medication Management Program in a Veteran Population

(1-032) Improving Tobacco Use Screenings Among Veterans at Jesse Brown Veterans Affairs Medical Center

(1-033) Assessing Effect of Transitioning from Semaglutide to Tirzepatide

(1-034) Retrospective Analysis of Urinary Tract Infections in Veterans on Empagliflozin

(1-035) Influence of Continuous Glucose Monitors and Glycemic Control in Veterans with Diabetes Mellitus at VA Central Iowa

(1-036) Association Between Adherence to Continuous Glucose Monitor and Hemoglobin A1c in Veterans

(1-037) Impact of Semaglutide versus Tirzepatide on Daily Insulin Requirements

(1-038) Evaluation of outcomes with injectable weight loss medications managed by a clinical pharmacist practitioner

(1-039) Dashboard Driven Care: Sodium Glucose Cotransporter-2 Inhibitor Utilization in Veterans with Concurrent Diabetes Mellitus, Heart Failure, Kidney Disease, and Atherosclerotic Cardiovascular Disease

(1-040) Implementation of a Pharmacist-Led Shared Medical Appointment for Weight Management at a Veterans Affairs Medical Center

(1-041) Assessing Tolerability of Switching from Maximum Dose Semaglutide to Tirzepatide for Weight Loss in the Veteran Population

(1-042) Impact of Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP1RA in Veterans with Type 1 Diabetes and Obesity on Insulin Pumps

(1-043) Optimization of Clinical Pharmacy Practitioner Efficiency and Veteran Satisfaction Through Cancellation Rate Analysis and CGM Class Expansion

(1-044) The Implementation and Impact of Weight Management Services within Pharmacy Primary Care

(1-045) Implementation of Indian Health Service (IHS) Asthma Control in Tribal Communities (ACT) Initiative to Improve Asthma-Related Outcomes in a Primary Care Setting

(1-046) Impact of Depression on Glycemic Variability in Veterans with Type 2 Diabetes

(1-047) Evaluation of Patient-Aligned Care Team (PACT) Clinical Pharmacist Practitioner (CPP) Monitoring of Brand Name Levothyroxine to Generic Conversion

(1-048) Developing Pharmacist-Lead, Multidisciplinary Shared Medical Appointments for Veteran Outpatients Initiating Weight Management Medications

(1-049) Impact of Clinical Pharmacist Practitioners on Testosterone Management in Primary Care

(1-050) Pharmacist-Led Urate-Lowering Therapy Optimization for Gout Management in a Veterans Health Administration Setting

(1-051) Increasing Pharmacologic Treatment for Patients with Alcohol Use Disorder through Primary Care Clinical Pharmacy Practitioner Management

(1-052) Assessing Benefit of Therapeutics for Hypertriglyceridemia: A Single Center Experience within the Indian Health Service

(1-053) Evaluating Glycemic Control in Type 2 Diabetes Patients Across Pharmacist-Led and Collaborative Care Models

(1-054) Trends in Weight and Dosing for Veteran's on Glucagon Like Peptide 1 Receptor Agonist (GLP-1RA) Therapy Beyond One Year

(1-055) Evaluating the Concordance of Continuous Glucose Monitor (CGM) Prescribing with Facility Guidelines at the Veterans Affairs Hudson Valley Health Care System (VAHVHCS)

(1-056) Optimizing Migraine Management in Veterans: A Pharmacist-Led Review of Triptan Use in Primary Care Clinics

(1-057) Assessing the Utilization and Efficacy of Semaglutide, Liraglutide, and Tirzepatide for Weight Loss in the Veteran Population

(1-058) Filtering Chronic Kidney Disease Early: Improving Stage 2 CKD Identification and Risk Factor Management in a Rural Primary Care Clinic

(1-059) Evaluation of Vitamin D Testing and Supplementation in Veterans at the Chillicothe Veterans Affairs Medical Center (VAMC)

(1-060) Tirzepatide for Diabetes and Reduction in Total Daily Dose of Insulin

(1-061) Chronic Kidney Disease Progression in Veterans on ACEI/ARB with or without Empagliflozin: A Propensity Score Matched Analysis

(1-062) Impact of Pharmacist-Led Weight Management on Outcomes in Severe Obesity

(1-063) Impact of Pharmacist-Led Antidepressant Optimization in a Tribally-Operated Primary Care Clinic

(1-065) Efficacy of Buprenorphine Transdermal Patches in Chronic Pain Treatment when Transitioning from Full Opioid Agonists.

(1-066) Effects of Continuous Glucose Monitors (CGMs) on Hemoglobin A1C Levels in Veterans with Diabetes

(1-067) Enhancing Iron Deficiency Anemia Care Through Clinic Implementation

(1-068) Evaluation of Rates of Alcohol Use Screening Among Veterans in a Primary Care Setting at the Providence VA Facility

(1-069) Medication Use Evaluation of Levothyroxine Prescribing for Initial Management of Hypothyroidism at the Veterans Affairs Providence Healthcare System

(1-070) Evaluation of Sodium-Glucose Co-Transporter 2 Inhibitor Utilization and Laboratory Monitoring at the Veterans Affairs Providence Healthcare System (VAPHS)

(1-071) Evaluation of Monitoring Processes Following Semaglutide Initiation in Patients with Type-Two Diabetes at the Columbia VA HCS

(1-072) Quality Assessment of Implementation of “Potential SGLT2 Candidate by Appointment Dashboard”, a VA Population Management Tool in the Primary Care Setting

(1-073) Implementation of Share My Health Data (SMHD) to Streamline Hypertension Care

(1-074) Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), Glucose-Dependent Insulinotropic Polypeptide/GLP-1 RA (GIP/GLP-1RA) and Associated Gallbladder Risk in Type 2 Diabetes (T2DM)

(1-075) Expanding Access to Insulin Pump Systems in Adults with Type 2 Diabetes in a Veterans Affairs Clinical Pharmacist-Led Clinic

(1-076) Effectiveness of Tirzepatide after Inadequate Response to Semaglutide for Weight Loss: A Retrospective Analysis

(1-077) The Great D-bate: Evaluating Cholecalciferol and Ergocalciferol Once Weekly Supplementation for  Vitamin D Repletion

(1-078) STEPS (Semaglutide Therapy Efficacy and Persistence Study) Ahead

(1-079) Improving Screening for Osteoporosis and Treatment Candidacy for Veterans in Home Based Primary Care

(1-080) Investigation of Immunization Rates and Population Demographics of Vaccination Refusal

(1-081) Evidence-Based Deprescribing of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease by Pharmacists at VA Salt Lake City Healthcare System

(1-082) The Impact of VA Clinical Pharmacist Interventions on Medication Management Post-Discharge in the Transition of Care Clinic

(1-083) Optimization of GLP-1/GIP Medication Utilization within high-risk veteran populations

(1-084) Evaluation of Inhaled Corticosteroid (ICS) Prescribing Patterns in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Retrospective Chart Review

(1-085) Retrial of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Following Genitourinary Infections (GUIs) in Adults with Type 2 Diabetes Mellitus (T2DM): Impact on Recurrence and Glycemic Control

(1-086) From Nurse to Pharmacist: Improving Gaps in Interdisciplinary Hypertension Management via a Nurse-Driven Pathway

(1-087) Analyzing the impact of a formulary conversion from alogliptin to sitagliptin on Veterans at the Hershel “Woody” Williams VA Medical Center.

(1-088) Enhancing Veteran Primary Care Services Through Optimization of Clinical Pharmacist Practitioner (CPP) Staffing Ratios

(1-089) Clinical Pharmacy Practitioner Impact on Veteran Care Post-Bariatric Surgery

(1-090) Outreach to High-Risk Veterans with Lower Levels of Engagement in Tobacco Treatment Services

(1-091) Impact of Implementing a Self-Directed Care Pharmacist Role into Veteran's Affairs Patient Aligned Care Teams

(1-092) Use of Long-Acting Injectable (LAI) Mental Health Medications and Boosting Prescriber Confidence Through Targeted Education.

(1-093) Improvement of testosterone lab draw timing for biological male patients at Cheyenne Veteran Affairs Health Care System (CVAHCS).

(1-094) Deprescribing Sulfonylureas in Older Veterans with Well-Controlled Type 2 Diabetes at a Rural Veterans Affairs Health Care System

(2-005) Evaluating the Implementation of Services Targeting Medication Adherence in Adults with Non-Dialysis Chronic Kidney Disease

(2-020) Optimizing Pharmacy Care Management: Strategies for Identifying and Discontinuing Unnecessary Medications in Patients with Extreme Polypharmacy to Improve Adherence and Safety

(2-022) Collaborative Drug-Therapy Management for Pharmacist-Led Hypertension Clinic

(2-070) A Retrospective Analysis of Hypocalcemia Observed in Osteoporosis Patients with Reduced Kidney Function Receiving Prolia

(2-085) Exploring a Potential Link Between GLP-1 Receptor Agonists and Myodesopsia

(2-087) Clinical Pharmacist Interventions on Diabetes Preventative Care Measures in Spanish-Speaking Patients

(2-089) Evaluating Clinical Pharmacist Interventions on Glycemic Control in Spanish-Speaking Patients with Uncontrolled Type 2 Diabetes

(2-090) Implementing Diabetes Care Plans to Improve Diabetes Preventative Care Screenings

(2-092) Impact of Diabetes Care Planning on Glycemic Control in an Underserved Setting

(2-097) Assessment of the Therapeutic Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Headache-Related Conditions

(2-116) Assessing the Impact of the Pharm2Home Initiative on Medication Adherence

(2-118) Implementation of an Intensive Post-Discharge GDMT Optimization Pilot in Heart Failure

(2-126) Impact of Pharmacists on Glucocorticoid Exposure in Rheumatology Patients

(2-153) Guideline-Directed Medical Therapy (GDMT) Utilization and Survival Rates in the Left Ventricular Assist Device (LVAD) Population

(2-182) Kidney Health Evaluation for Patients with Diabetes Measure Performance Snapshot

(2-189) Protocol Development for Pharmacist-Led Conversion to Single Pill Combination Therapy in Patients with Hypertension

(2-194) Utilization of Validated Home Blood Pressure Monitors to Advance Quality Improvement Measure in Hypertension Care at an Internal Medicine Clinic

(2-196) Primary Care Provider Perspectives on Collaborative Practice Agreements with Pharmacists

(2-208) Medicaid Reimbursement for Pharmacist’s Clinical Services Across the United States

(2-210) An Analysis of Services Provided by Embedded Pharmacists in Primary Care Settings

(2-226) Barriers to Accessing Glucagon-like peptide-1 (GLP-1) Medications: A Patient-reported Outcomes Survey

(2-294) Impact of Formulary Changes: A Medication Use Evaluation of Tirzepatide in Chronic Weight Management

(2-305) De-Escalating Inhaled Corticosteroid (ICS) in Patients with Chronic Obstructive Pulmonary Disease (COPD)

(2-336) Thigh skin infection following alternate site placement of a continuous glucose monitor sensor

(2-343) Development of a Student-Pharmacist Led Medication Review Initiative to Support Appropriate Medication Use in Older Adults

(2-358) Evaluation and Referral Patterns for MASLD/MASH Risk in Patients with Type 2 Diabetes at a Free Clinic

(2-359) Evaluating the Impact of GLP1-RA and SGLT2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease

(2-363) Evaluating Patient Perceptions of Skin Disease during Pharmacist Interventions in Atopic Dermatitis

(2-366) Evaluation of statin prescribing practices for patients in the statin use in persons with diabetes (SUPD) quality measure

(2-368) Predictive factors associated with progression of healthcare utilization and hospitalization in patients with sickle cell disease

(2-382) Evaluating the Impact of a Pharmacist-integrated Primary Care Team on Hospitalizations and Emergency Department Visits in an Uninsured Population

(2-390) Impact of Pharmacist Care Team Integration in the Primary Care Setting on Preserving Renal Function in Uninsured Patients

(3-007) National Prescribing Trends of Metformin Before and After the 2022 Treatment Guideline Update

(3-009) Analysis of Prescribing Patterns of Incretin-Based Therapies in Patients with Type 2 Diabetes in a Primary Care Clinic

(3-010) Evaluation of Sodium Glucose Cotransporter 2 Inhibitor Use in Patients with Type 2 Diabetes in a Primary Care Clinic

(3-022) Pharmacist Integration in a Cystic Fibrosis Clinic: Evaluation of Patient Access

(3-044) Early Detection of Chronic Kidney Disease in High-Risk Jamaican Communities

(3-084) Evaluating the Implementation and Effectiveness of a Pharmacist-Led Smoking Cessation Initiative in an Anticoagulation Therapy Clinic: A Retrospective Analysis

(3-096) Use of Finerenone for CKD in Type 2 Diabetes: A Cross-Sectional Study at a Large Health System

(3-121) Feasibility of a Pharmacist-Lead Cardiometabolic Service in an Ambulatory Care Setting

(3-122) Scaling Pharmacist-Physician Co-Visit Models: Sustained Reimbursement Opportunities in Federally Qualified Health Centers

(3-139) Promoting the HPV Vaccine Immunization in Systemic Lupus Erythematosus (SLE) Patients: A Pharmacist-Led Educational Intervention

(3-145) Hemoglobin A1C vs. GMI in College Students without Diabetes

(3-208) Adjustment of warfarin dosing due to drug interactions with antimicrobial agents in a pharmacist managed anticoagulation clinic

(3-209) Bridging the Gap: Discharge Hydralazine Prescribing for Hypertension in patients with CKD and/or ASCVD

(3-218) Assessing Diabetes Care: Impact of Manufacturer Support Programs in a Diabetes Clinic

(3-221) Closing the Gap in Lipid-Lowering Therapy: A Pharmacist-Driven Approach for Patients with Atherosclerotic Cardiovascular Disease (ASCVD)

(3-224) Impact of Health Coaching on Lipid Management at a Veterans Affairs Medical Center

(3-227) Beyond diabetes and obesity: the role of GLP 1 agonists in alcohol use disorder

(3-238) Semaglutide-Induced Allodynia: Two Case Reports in Chronic Weight Management

(3-240) Patient Perspectives on Pharmacy Support Services for Medication Management ​

(3-242) Pharmacist-Directed Transition to Automated Insulin Delivery in Two Adults with Type 2 Diabetes: Impact on Glycemic Outcomes and Insulin Use

(3-248) Impact of Tirzepatide on Alcohol Consumption: A Case Report Highlighting the Potential Utility of Reduced Alcohol Intake

(3-249) Complete insulin discontinuation and glycemic stabilization with low-dose tirzepatide: a pharmacist-led case suggestive of pharmacogenomic variability

(3-253) Detection of Endogenous Hypercortisolism During Management of Type 2 Diabetes in an Ambulatory Care Clinic

(3-254) Heart Failure: When the Flow Runs Low

(3-259) Statin intolerance in HMG-CoA reductase antibody–positive myopathy: a clinical case report

(3-264) Integrating Acute Care Planning into Chronic Pain Management: A Case-Based Approach

(3-274) Assessing the Prescribing Practices of Glucagon-Like Peptide-1 Receptor Agonists Among Ambulatory Care Pharmacists in Patients with Elevated Fibrosis-4 Scores

(3-276) Optimizing the Medication Ordering Process Through Real-Time Prescription Benefits (RTPB) Utilization

(3-293) Impact of glucagon-like peptide-1 (GLP-1) agonists on hypertension quality metrics

(3-295) Clinical Impact of Sodium-Glucose-Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction in Advanced Primary Care

(3-314) Impact of Pharmacist Services in an Ambulatory Psychiatry Clinic

(3-322) Evaluation of Pharmacist Comprehensive Medication Review Prior to Annual Wellness Visits in Geriatric Patients

(3-337) Evaluation of the Impact of Switching from Glucagon–like Peptide-1 Receptor Agonist to Tirzepatide on the Lipid Profile in Patients with Type 2 Diabetes

(3-349) Real Life Outcomes with Glucagon-Like Peptide 1 Weight Management in Pediatric Patients

(3-350) Nonprofit Organization and School of Pharmacy Collaboration to Transform Diabetes Care in Underserved Rural Populations: Interim Pilot Study Results of Telehealth Medication Therapy Management (MTM)

(3-354) Use of Tirzepatide for Lipid Modulation in Type 2 Diabetes Mellitus

(3-357) Impact of a Physician-Pharmacist Collaborative Continuous Glucose Monitoring (CGM) Service on Real-world Patient Outcomes in Type 2 Diabetes Mellitus: a Retrospective Analysis

(3-371) Expanding Access to Chronic Disease Management: Pharmacist Integration in Rural Family Medicine

(3-384) Dupilumab vs. Tralokinumab in adolescent patients at Children's Mercy clinics: a comparison of benefit and adverse effects

(4-008) Advancing Outcomes in Cystic Fibrosis: The Impact of Expanded Pharmacist Scope in Outpatient Care

(4-009) Alkaline Phosphatase and Gamma-Glutamyl Transferase Improve Diagnosis Accuracy in Patients with Liver Diseases

(5-197) Evaluation of Asthma Rescue Inhalers with and without an Inhaled Corticosteroid

(5-213) A Multi-Site Prospective Review on the Use of Continuous Glucose Monitoring in Patients Living With HIV and Diabetes

(5-244) Effectiveness of Medication Interventions to Prevent Suicide in the in the Department of Veterans Affairs: A Scoping Review

(5-269) Implementation of a Proton Pump Inhibitor Deprescribing Protocol in an Ambulatory Care Setting

(5-277) Evaluation of Guideline-Directed Medication Therapy in Primary Care Patients with Hypertension and Albuminuria

(5-292) Glucagon-Like Peptide-1(GLP-1) Receptor Agonist Utilization and Access in a Family Medicine Clinic

(5-304) Efficacy and Safety of Adenosine Versus Calcium Channel Blockers in the Treatment of Supraventricular Tachycardia: A Systematic Review

(6-007) Review of Student Pharmacist Involvement in Diabetes Control Quality Metric for Medicare Patient Population

(6-012) Evaluation of Insulin Administration and Patient Satisfaction with the Use of CeQur Simplicity Insulin Patch (SIP)

(6-013) Retrospective Evaluation of Patient Assistance Program Resources (Medication Access Pharmacy Technicians) within the Pharmacy Connect Department

(6-025) Evaluation of Social Determinants of Health for People with Uncontrolled Hypertension Enrolled in the Heart to Heart: Blood Pressure Control Partners Study in North Carolina

(6-060) Identifying Broader Social Needs in Patients With Medication Cost Concerns: Pharmacy Technician-Led Screening Initiative

(6-090) Pharmacists’ Impact on Therapy Optimization in Pulmonary Diseases within Ambulatory Clinic Setting.

(6-097) Comparison of Antihemophilic Agents on Annualized Bleeding Rates

(6-106) Evaluation of prescribing practices of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in women of childbearing age in primary care: a quality improvement project

(6-112) Implementation of Pharmacy Intern Program for Professional Development in Ambulatory Care Setting

(6-115) Pharmacist Led Patient Survery Identifying Barriers to COPD Management

(6-127) Cross-Sectional Survey of Patient Perceptions and Satisfaction of a Resident-Run Substance Use Disorder Clinic Using the Client Satisfaction Questionnaire 8 Survey.

(6-132) Effects of Medication Adherence Counselors on Clinical Outcomes in Patients with Diabetes

(6-157) Shifting the Paradigm: Screening for Type 1 Diabetes to Prevent Diabetic Ketoacidosis and Long-Term Complications

(6-162) Navigating Prescription Cost Saving and Assistance Opportunities to Optimize Medication Access in the Primary Care Setting

(6-203) Evaluating Prescribing Opportunities for Sodium-Glucose Cotransporter 2 Inhibitors in Medicare Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease on Sulfonylurea Therapy

(6-233) Statin initiation and adherence following population health pharmacist intervention

(6-236) Provider Visit Outcomes for Statin-Hesitant Patients Following Pharmacist Intervention in Outpatient Primary Care Practices

(6-247) Predictors of SGLT-2 inhibitors Use in Type 2 Diabetes Mellitus at an Urban Academic Outpatient Internal Medicine Clinic

(6-258) Uncovering the Treatment Gap: COPD Exacerbations in Patients Without LABA or LAMA Therapy

(6-262) Fall Risk Increasing Drugs and Fall History in Older Adults

(6-279) Patient Knowledge and Confidence with Warfarin Therapy: Impact on Therapeutic Time in Range

(6-282) Doxycycline-Induced Hypoglycemia in an Older Adult with Well-Managed Insulin Dependent Diabetes

(6-287) Connecting Patients in Hypertension Care: A Pilot of Remote Cellular-Enabled Blood Pressure Monitoring in Primary Care

(6-293) ADHERE-BP: A Pilot Academic Detailing Quality Improvement Initiative to Strengthen Evidence-Based Hypertension Management

(6-295) Assessing the Safety and Efficacy of Weight Management Medications in Patients Managed by a Clinical Pharmacist Practitioner at a Veteran Affairs Medical Center

(6-321) De-escalating Diabetes Mellitus Treatment in VA Patients Using Hypoglycemia Dashboard

(6-323) Expanding Guideline-Directed Heart Failure Therapy: A Pharmacist-Led Service to Increase Empagliflozin Use at a Veterans Affairs Medical Center

(6-329) Pharmacist Interventions in Chronic Disease Management: Patient Perspectives and Subjective Clinical Outcomes

(6-331) Evolution of Pharmacist-Led Medicare Annual Wellness Visits in a Federally Qualified Health Center in a Medically Underserved Area

(6-358) Continuous Glucose Monitoring Systems Interpretation and Billing in Pregnancy

(7-001) Improving Confidence and Preparedness in Diabetes Management During Ramadan: A Community Education Approach

(7-064) When the Shot Stops: A Scoping Review of Weight Trajectory and Metabolic Outcomes After Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Discontinuation

(7-073) Identifying Barriers to Medication Adherence in Dermatology and Endocrinology Patients Using the Validated 15-STARS Questionnaire

(7-093) Pressure and Progression: Interim Analysis Evaluating Blood Pressure Outcomes of Sodium Glucose Cotransporter-2 Inhibitors (SGLT-2i) in Patients With and Without Chronic Kidney Disease

(7-145) Semaglutide Use in a Patient with a Long-Term Ileostomy: A Case Report Highlighting Clinical Risks and Evidence Gaps

(7-149) Evaluation of Patient-Reported Outcomes Using Hidradenitis Suppurative Quality of Life Surveys to Support Patient Management in an Outpatient Clinical Setting

(7-159) Same Drug, Different Pressure: Interim Analysis of Blood Pressure Outcomes of Sodium Glucose Cotransporter-2 Inhibitors (SGLT-2i) Effects in Hypertensive and Normotensive Populations

(7-189) Measuring Impact on Health Outcomes Through Culturally Tailored Diabetes Education in Underserved Populations

(7-250) Closing The Gap: Expanding Access to Continuous Glucose Monitoring: Barriers, Motivators and Opportunities for Change

(7-255) Implementing an Interdisciplinary Formulary to Improve Access and Outcomes for Uninsured Patients at a Federally Qualified Health Center

(7-260) Continuous Glucose Monitors: A less invasive approach to monitoring blood glucose and promoting healthier lifestyle choices in patients living with Diabetes Mellitus

(7-274) Insurance Coverage Changes Impacting Continuous Glucose Monitor Access and the Effect on Diabetes Control

(7-283) Evaluation of Reason for Referral to Embedded Clinical Pharmacist in a Medical Weight Management Clinic at One Health System Outpatient Clinic

(7-303) Evaluating the Management of Peripheral Artery Disease in Veterans in a Primary Care Setting

(7-317) Assessing the Efficacy of Ramelteon in the Management of Insomnia among Veterans with Previous Melatonin Ineffectiveness

(7-334) Glycemic outcomes following discontinuation of a glucagon like peptide receptor agonist patient assistance program

(8-009) Comparative Effectiveness of Once-weekly Basal Insulins vs. Daily Glargine in Type 2 Diabetes: a Bayesian Meta-Analysis of Randomized Trials

(8-010) Empowering Pharmacists in Cognitive Health: the Alzheimer's Disease Continuum and Dementia Risk Reduction

(8-011) Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence

(8-012) Feasibility, Acceptability, Appropriateness, and Preliminary Effectiveness of a Telehealth-based Clinical Pharmacy Program Among Patients with Type 2 Diabetes at Rural Primary Care Settings

(8-013) Evaluating the Impact of Pharmacist-Led Obesity Management versus Traditional Care on Clinical Outcomes: A Retrospective Analysis of Real-World Adult Patients

(8-014) Redefining the Role and Impact of an Ambulatory Care Pharmacist on Guideline-directed Prescribing Within an Endocrinology Clinic

(8-035) Assessing Barriers and Facilitators of Sodium-glucose cotransporter-2 Inhibitor Prescribing in Patients with Concomitant Type 2 Diabetes Mellitus and Heart Failure in a Primary Care Setting

(9-007) Evaluating the Impact of Clinical Pharmacist Involvement within a Multidisciplinary Antiretroviral Clinic on Human Immunodeficiency Virus Management in a Federally Qualified Health Center

(9-008) Evaluating Hemoglobin A1C Outcomes in an Interdisciplinary Diabetes Clinic With Pharmacist Integration

(9-043) Prescribed Steroid Bursts as an Indicator of Chronic Obstructive Pulmonary Disease and Asthma Control: A Retrospective Chart Review

(9-063) Pharmacist-led Pediatric Asthma Clinic: Improving Asthma Control in Pediatric Patients at a Rural Federally Qualified Health Care Center

(9-064) Optimizing Anticoagulation Clinic: Impact of converting warfarin patients to direct oral anticoagulants or home INR monitoring services, while assessing clinic capacity for new service expansion.

(9-065) Implementation of a Pharmacist-supported Transition of Care (TOC) Process within an Ambulatory Care Setting

(9-075) Implementation of Pharmacogenomic Testing to Guide Antiplatelet Therapy in Patients Prescribed Clopidogrel at Sun Life Health

(9-076) Impact of Clinical Pharmacy Diabetes Management on Diabetes-Related Medicare Star Metrics

(9-083) Impact of Automated Insulin Delivery on Glycemic Outcomes in Adults with Type 2 Diabetes Mellitus (T2DM) in a Rural Federally Qualified Health Center (FQHC) Setting

(9-084) Characterizing Clinical Pharmacy Performed Medication Reconciliation as Part of Integrated Medication-Assisted Treatment Visits

(9-100) Effect of GLP-1 Agonists on INR in Patients on Warfarin

(9-106) Pharmacist-Directed Evaluation of Artificial Intelligence–Generated Recommendations to Enhance Guideline-Directed Medical Therapy in Heart Failure

(9-144) Evaluating Real-World Effectiveness and Adherence of Glucagon-Like Peptide-1 Receptor Agonists in Adults with Type 2 Diabetes at a Safety-Net Hospital

(9-158) Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Health Outcomes Project Evaluation (HOPE): Examining Pharmacy Prescription Dispensing and Patient Refill Patterns

(9-169) Impact of Post-Discharge Transitions of Care Pharmacist Integration in Primary Care Clinics

(9-173) Evaluating Outcomes of a Clinical Pharmacy Program with Community Provider Groups

(9-187) Interdisciplinary Delivery of Basic Ambulatory Care to Underserved Populations in Tecate, Mexico

(9-188) Association Between Adherence to Monthly IM Naltrexone and Clinical Outcomes in a Pharmacist-Led Addiction Medicine Clinic for Alcohol Use Disorder

(9-197) Developing and Evaluating Clinical Documentation Tool in Transition of Care Setting

(9-200) Evaluating the Effect of a Pharmacist-led Education on Referrals for Benzodiazepine Tapers and Deprescribing in an Ambulatory Care Setting

(9-235) Impact of Pharmacist-Led Titration of GLP-1 and GIP/GLP-1 Receptor Agonist: Effects on Weight Loss in Endocrinology and Cardiometabolic Clinics

(9-236) POUNCE Protocol: Pharmacist-Led Optimization of PCSK9 Inhibitor Utilization Through Sample Distribution and New-Start Counseling with Education

(9-246) Assessment of the management of patients in primary care setting with stage 2 hypertension, based on guidelines.

(9-247) Evaluating the Impact of a Pharmacist-Led Diabetes Optimization in Transitions of Care (DOT-TOC) Program on Post-Discharge Outcomes

(9-252) Deprescribing of Multiple Anticholinergics in Patients Over 65 Years Old in the Primary Care Setting

(9-253) Impact of Pharmacist Intervention on Chronic Kidney Disease Screening and Optimization of Guideline Directed Medical Therapy in Adult Patients with Type 2 Diabetes

(9-277) Evaluation of Prescribing Patterns and Utilization of the “Ambulatory Hypertension” Care Signature Pathway

(9-281) Evaluation of Prescribing Patterns and Utilization of the Hyperlipidemia Care Signature Pathway

(9-282) Evaluation of Prescribing Patterns and Utilization of the “Overactive bladder and Urge/Stress incontinence for Women” Care Signature Pathway

(9-283) Evaluation of Prescribing Patterns and Utilization of the Adult Ambulatory Uncomplicated Urinary Tract Infection (UTI) Care Signature Pathway.

(9-285) Assessing the Acceptance of Medication Recommendations Made by Pharmacists to Licensed Practitioners and the Impact on Polypharmacy Management

(9-311) Impact of Clinical Pharmacists on Glycemic Control in Primary Care Patients with Diabetes

(9-312) Impact of Pharmacist and Care Management Nurse Collaboration on Social Determinants of Health, Fiscal Outcomes, and Quality Improvement

(9-328) Restoring Control: A Medication Use Evaluation of Vibegron in the Treatment of Overactive Bladder

(9-363) Impact of Pharmacist-Led Post-Discharge Medication Reconciliation for High-Risk Patients

(9-371) Impact of Pharmacist-Led Medication Therapy Management and Pillbox Interventions on Adherence in Polypharmacy Patients at a Federally Qualified Health Center

(9-403) Evaluation of Prescribing Trends for Heart Failure Patients in the Ambulatory Setting

(9-480) Leveraging Telehealth Interventions for Early Adherence Support in Heart Failure Optimization

(9-485) Evaluation of Clinical Pharmacist Involvement in Reducing Anticholinergic Cognitive Burden: A Medication Review Initiative

(10-007) Impact of Amlodipine to Nifedipine Conversions by a Remote Pharmacy Hypertension Service

(10-008) Evaluation of lipid profiles in patients taking tumor necrosis factor alpha inhibitors for Inflammatory Bowel Disease

(10-010) Real World Conversion from NPH to Insulin Glargine-yfgn in an Outpatient Clinic Setting

(10-035) Comparison of Hemoglobin A1C Reduction Using Continuous Versus Remote Blood Glucose Monitoring in Insulin Dependent Adults with Type 2 Diabetes: A Retrospective Cohort Study

(10-038) Enhancing Osteoporosis Management: An Emphasis on Bisphosphonate Optimization

(10-121) Comparison of Warfarin Efficacy and Safety in Youngest-Old, Middle-Old, and Oldest-Old Patients with Atrial Fibrillation Enrolled in a Pharmacist-Managed Anticoagulation Clinic

(10-128) Impact of Pharmacist-Led Ambulatory Care Visits for the Optimization of Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction.

(10-154) o Enhancing Patient Access to Manufacturer Financial Assistance Programs for Ambulatory Infused Medications: A Quality Improvement Initiative at a Single Community Hospital

(10-155) Evaluation of Discontinuation Rates of Incretin-Based Pharmacotherapy in Type 2 Diabetes: Pharmacist vs. Standard of Care Management

(10-166) Evaluating Provider Productivity and Reimbursement in a Provider-Pharmacist Co-visit Model Compared to Pharmacist-Only Visits for Medicare Annual Wellness Visits

(10-168) Evaluation of Pharmacist Impact in Healthy Aging Transition Services (HATS)

(10-173) Anabolic Agent Use in Osteoporosis: The Role of Pharmacist Involvement and Health System Cost Analysis

(10-202) Evaluating a Clinical Pharmacist’s Role at a Graduate Medical Education Primary Care Residency Clinic

(10-209) Assessing the Impact of Inpatient-to-Outpatient Heart Failure Clinic Transitions of Care on Patient Safety

(10-210) Evaluating the Prevalence of Multiple Anticholinergic Medication Use in Older Adults Utilizing POLY-ACH Criteria

(10-213) Basal Burden: Risk Factors for Overbasalization in Type 2 Diabetes Mellitus in Primary Care

(10-249) Evaluation of Continuous Glucose Monitors for Glycemic Evaluation and Screening of Cystic Fibrosis-Related Diabetes

(10-266) Real Life Effect of Biologic Therapy Initiation in Cumulative Non-Inhaled Corticosteroid Use for Asthma Control at a Single Academic Medical Center

(10-271) Effectiveness of Off-Label Increased Dosing of Omalizumab Compared to Standard Dosing for Chronic Spontaneous Urticaria

(10-279) Integrating Pharmacists into the Primary Care Team

(10-281) Implementation of a Pharmacist-Managed Mavacamten Clinic

(10-316) Pharmacist-Led Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Quality Improvement Project for At-Risk Adults at a Federally Qualified Health Center

(10-337) Glycemic Outcomes Associated with Professional Continuous Glucose Monitoring in a Family Medicine Resident Clinic

(10-346) An Exploratory Study to Assess the Relationship of Urogenital Infection Rate and HbA1c Level Among Patients with Type 2 Diabetes who are Taking Empagliflozin

(10-354) Pharmacist impact on Medicare HEDIS measures in primary care offices

(10-360) Impact of a Transitions of Care Pharmacy Program on Hospital Readmission Rates

(10-365) The impact of pharmacist-managed weight management service on weight loss and associated clinical outcomes

(10-367) Impact of a Clinical Pharmacy Diabetes Service on Glycemic Outcomes in Patients Newly Initiated on GLP-1 Receptor Agonists

(10-368) Impact of Clinical Pharmacy Involvement in Patients Naïve to Direct Oral Anticoagulants (DOACs)

(10-391) Pharmacist-Led Evaluation of Direct Oral Anticoagulant Prescribing Appropriateness in Ambulatory Care

(10-405) Evaluating Health Equity and Access to Apretude (Cabotegravir) for HIV Pre-Exposure Prophylaxis at a Large Academic Medical Center within a Metropolitan City

(10-406) Evaluating the Impact of GLP-1 Based Therapy for Obesity on TSH Levels in Patients with Hypothyroidism

(10-411) Improving Recombinant Zoster Vaccine Utilization Among Specialty Clinic Patients Prescribed Immunosuppressive Therapies

(10-414) Protocol-driven medication management of IgA Nephropathy (IgAN) in an interdisciplinary outpatient renal medicine clinic

(10-418) Implementation of a Pharmacist-Led Periprocedural Antiplatelet Management Service

(10-427) Evaluating the Impact of a Pharmacist-Led Heart Failure Clinic in the Use of Guideline-Directed Medical Therapy of Patients with Heart Failure with Reduced Ejection Fraction

(10-428) Evaluating the Impact of Pharmacy Technician-Led Clinics for Prediabetes A1c Screening to Improve Early Detection of Disease Progression

(10-433) Evaluating the Impact of Universal Low-Dose Aspirin Prophylaxis on Preeclampsia Rates at a Federally Qualified Health Center

(10-434) Pharmacist-Led CGM Visit Frequency and Its Relationship to Glycemic Control at a Federally Qualified Health Center

(10-441) Transitioning from Tirzepatide to Semaglutide: A Real-World Evaluation in Ambulatory Care Patients

(11-013) Evaluating the Impact of an Interprofessional Deprescribing Protocol on Polypharmacy and Student Learning in Geriatric Patients: A Pre-Post Study

(11-015) Evaluation of Pharmacist Impact on Blood Pressure Management in an Ambulatory Care Cardiology Clinic

(11-018) Vitamin B12 Monitoring in Metformin Users: Are We Missing an Opportunity for Safer Diabetes Care?

(11-023) PHARM-ED: Pharmacist-Enhanced Hypertension Management in the Emergency Department

(11-062) Evaluation of Dapagliflozin Dosing for Congestive Heart Failure (CHF) and Chronic Kidney Disease (CKD) in the Primary Care Setting

(11-073) Utilizing Kotter’s 8 Step Process for Change to Expand Comprehensive Medication Management Services at Aspirus St. Luke’s

(11-075) Finding Care Gaps in Patients Eligible for the Pneumococcal 21-valent Conjugate Vaccine

(11-085) Investigating Patient Characteristics Associated with Greatest Weight Loss Benefit in Patients Taking GLP-1 Receptor Agonists

(11-087) Quality and Consistency of Warfarin Management Following Adoption of a Centralized Anticoagulation Management Model

(11-130) Evaluation of Peripheral Artery Disease Screening Practices in High-Risk Patients at a Federally Qualified Health Center in the Mississippi Delta

(11-132) Small Patients, Big Pressures: Evaluating the Efficacy and Safety of Antihypertensive Agents in Pediatrics

(11-133) Experience and Perceptions of Continuous Glucose Monitoring Use, Availability, and Access at a Federally Qualified Health Center

(11-134) Impact of GLP-1 Receptor Agonist Use on Patient Satisfaction in Type 2 Diabetes Treatment

(11-142) Impact of Integrating a Pharmacist in a Heart Failure Clinic on Readmission Rates: Phase II

(11-192) Impact of a Pharmacist-led Outpatient Antimicrobial Stewardship Program in an Urgent Care Setting

(11-221) From One Shot to the Next: Strategies for Transitioning to Tirzepatide

(11-249) RE-FLAME: Real-world Effectiveness of GLP-1 Agonists for Weight Loss in Family Medicine

(11-250) GOALE-DM: Glycemic Outcomes After Pharmacist-Led Education on Diabetes Management

(11-291) Optimizing pharmacotherapy to improve cardio-renal outcomes in patients with diabetic kidney disease at a community clinic

(11-293) Impact of a Pharmacist-Led Telemedicine Benzodiazepine Tapering Program

(11-297) Identifying Co-Prescribing Patterns and Barriers of Concurrent Use of Opioids and Benzodiazepines in the Outpatient Setting

(11-311) Rates of Adherence to American Diabetes Association Standards of Care Lipid-Lowering Recommendations for People with Diabetes and Clinical Atherosclerotic Cardiovascular Disease in Primary Care

(11-312) Integrating Pharmacist Expertise to Enhance Reproductive Health Counseling and Screening for Adolescents and Young Adults on Teratogenic Medications in Pediatric Rheumatology

(11-314) Assessing the Benefit of Pharmacist-led Early Continuous Glucose Monitor (CGM) Placement in Hospitalized Patients at Time of Discharge

(11-369) A real-world comparative analysis of maximum-dose semaglutide versus tirzepatide on weight reduction and metabolic outcomes in overweight and obese individuals

(11-411) Glycemic Outcomes of Patients with Type 2 Diabetes Mellitus Using FreeStyle Libre versus Dexcom Continuous Glucose Monitors in an Urban Ambulatory Care Clinic

(11-413) De-escalation of Incretin Based Therapy: Implications for Weight, Glycemic Control, and Safety in Patients with Type 2 Diabetes Mellitus in Ambulatory Care Clinics

(11-422) Identifying and Addressing Overbasalization in Outpatient Insulin Therapy Using CGM Data

(11-424) Evaluating Sulfonylurea Use and Opportunities for Safer and More Effective Alternatives in an Urban Outpatient Clinic

(12-036) Evaluating Benzodiazepine and Opioid Co-Prescribing Practices Among Medicare Patients in Cone Health Medical Group Clinics

(12-041) Assessment of Discharge Transitions of Care Consults with a Dedicated Transitions of Care Pharmacist Compared to a Floor Pharmacist

(12-045) Adjustments in Insulin Dosing After Initiation of a Glucagon-like Peptide-1 Receptor Antagonist(GLP-1 RA) or Combination GLP-1 RA/Glucose-dependent insulinotropic polypeptide(GIP) in Patients with Type 2 Diabetes

(12-053) Impact of an Interdisciplinary Lifestyle Medicine Program on Obesity Management

(12-057) Impact of Glucagon-Like Peptide-1 and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists on Glycemic Control and Insulin Requirements in Adults with Type 1 Diabetes

(12-059) Assessment of Cholesterol-Lowering Intensification Needs in Patients with Clinical ASCVD

(12-064) Impact of Intensive versus Standard Clinical Pharmacist Practitioner Management on Hemoglobin A1c Lowering Among Patients with Uncontrolled Diabetes

(12-070) Evaluating the Impact of Clinical Pharmacist Practitioners Interventions on Hospital Admission Rates and Clinical Outcomes in Patients with Diabetes

(12-081) Implementation of a Pharmacist-Led Heart Failure Guideline Directed Medication Therapy (GDMT) Optimization and Access Service in a Primary Care Setting

(12-104) Outcomes of a Pharmacist and Dietitian-led Weight Loss Clinic: A Retrospective Cohort Study

(12-136) Impact of Pharmacist Interventions on Optimizing Lipid Lowering Therapy in High-Risk Patients in a Primary Care Office

(12-147) Effect of Continuous Glucose Monitoring on Diabetes Distress Scale Score in Patients at a Family Medicine Practice

(12-154) Assessing Efficacy of GLP-1 and GLP-1/GIPs in a Real-World Population with Type 2 Diabetes

(12-168) Impact of Pharmacist-Managed Automated Insulin Delivery in a Federally Qualified Health Center

(12-179) Impact of Empagliflozin 25mg on Heart Failure Outcomes in Patients with Concurrent Type 2 Diabetes

(12-182) Evaluation of Effectiveness of Implementation of As-Needed Inhaled Corticosteroids for Asthma in a Safety-Net Health System

(12-183) Impact of Utilizing Continuous Glucose Monitoring at Hospital Discharge on A1c Reduction in Patients with Diabetes

(12-188) Comparing the effectiveness of Linagliptin vs. Sitagliptin in patients with Type 2 Diabetes Mellitus

(12-189) Pharmacist-Led Refill Authorization in Ambulatory Care: Advancing Workflow Efficiency and Patient Safety

(12-190) Depression as a Determinant of Glycemic Control in Patients with Type 2 Diabetes Mellitus

(12-195) Changes in Lipase and Incidence of Pancreatitis Among Patients Initiated on Glucagon-Like Peptide-1 Receptor Agonists

(12-198) Culture Callback Documentation Optimization

(12-200) Accuracy of Documented Allergies in the EMR

(12-245) Evaluating Real-World Outcomes of Long-Acting Injectable Antiretrovirals for HIV Treatment and Pre-exposure Prophylaxis in a Pharmacist-Managed Clinic Setting

(12-248) Comparison of Automated Insulin Delivery Systems on Blood Glucose Control in Patients with Type One Diabetes

(12-268) Description of denosumab utilization practices for the treatment of osteoporosis at Allegheny Health Network

(12-317) Evaluation of Apixaban Dosing Appropriateness in Patients with Atrial Fibrillation

(12-329) Evaluation of Inpatient Fracture Admission and Osteoporosis Follow-up Post Discharge

(12-331) Impact of a Pharmacist-Led Collaborative Drug Therapy Management for HIV Pre-exposure Prophylaxis on Patient Outcomes in a Family Medicine Clinic

(12-337) Characterization of Routine Assessment of Patient Index Data (RAPID3) Trends for Biologic Initiation and Treatment of Rheumatoid Arthritis

(12-376) Enhancing Access to PrEP through a Pharmacist Referral Protocol

(12-382) Evaluation of the Impact of Changes in Continuous Glucose Monitor (CGM) Insurance Coverage on Patients with Diabetes who are not Treated with Insulin

(12-411) Overbasalization in Type 2 Diabetes Mellitus (T2DM) Patients in Primary Care Offices

(12-415) Cost Savings Associated with Manufacturer Medication Assistance in Primary Care Clinics with Embedded Pharmacists

(12-429) Impact of Single-Pill Combination Antihypertensives on Hypertension and Adherence in a Medically Underserved Population within a Federally Qualified Health Center

(12-432) The Effects of Adding Tirzepatide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes Mellitus

(12-436) Impact of pharmacist-driven interventions on A1c reduction and glucose time in range for patients with CGM

(13-002) Analysis of U-100 vs U-200 Insulin Use in Insulin Pumps

(13-092) Evaluating the Impact of Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Reinitiation versus Discontinuation Post Hospitalization with Acute Kidney Injury on Patient Outcomes

(13-094) Clearing the Air: The Impact of a Pharmacist-led Pulmonary Medication Management Clinic

(13-099) Clinical and Financial Impact of Specialty Therapy Switching in Inflammatory Bowel Disease

(13-112) Physician and Resident Physician Perceptions of Pharmacists in Outpatient Clinics: A Comparative Study of Pharmacist-Based vs. Non-Pharmacist-Based Models

(13-129) Bridging Borders: A Structured Educational Initiative to Improve Diabetes Management in a Federally Qualified Health Center at the U.S.-Mexico Border

(13-135) Evaluation of Pharmacist-Led Education and Medication Management on Hemoglobin A1c and Compliance in a Rural Mid-South Ambulatory Setting

(13-138) Evaluation of Oral Factor Xa Inhibitors in Patients with Atrial Fibrillation and for Venous Thromboembolism Prevention and Treatment

(13-144) Effect of an Expanded Best Practice Advisory on Glucagon Prescribing in Patients with Diabetes at a Federally Qualified Health Center

(13-145) Impact of Clinical Pharmacy Services on Closing the Care Gap Among High-Risk Patients for Cardiovascular Events Not on Statin Therapy

(13-170) Evaluation of Outcomes with Long-Acting Cabotegravir/Rilpivirine at a County Clinic

(13-218) Retrospective Evaluation of Metformin vs GLP-1 and GLP-1/GIP Receptor Agonists for Glycemic Control and Diabetes Prevention in Adults with Prediabetes

(13-250) Evaluating Statin Prescribing Practices in Patients Living with HIV and HCV in a Northern Virginia Health System

(13-270) Evaluating the impact of prescribing clinical pharmacists on patient care and operational metrics in a primary care clinic

(13-300) Pharmacist Impact on HIV Care: Bridge to time of care and accessibility

(13-316) Bridging the Bone Gap: Implementing a Referral System for Pharmacist Led Osteoporosis Treatment to Prevent Future Fracture

(13-318) Optimizing Medication Reconciliation Workflow at a Family Medicine Clinic

(13-319) Optimizing Diabetes Standards of Care: Standardizing Insulin Pump Training and Documentation in Ambulatory Care Pharmacy

(13-321) Piloting a Pharmacist-Led Inclisiran Management Service to Evaluate Adherence and Economic Outcomes

(13-360) Impact of Pharmacy-Led Continuous Glucose Monitor Initiation on Type II Diabetic Patient Care in an Ambulatory Care Setting: A Retrospective Study.

(13-362) Evaluation of the use of SGLT2 Inhibitors for heart failure prescribed by providers in an urban health-system

(13-368) Comparative Impact of Metoprolol Succinate and Carvedilol on Optimization of Guideline-Directed Therapy in Heart Failure With Reduced Ejection Fraction

(13-384) Impact of a Pharmacist-led Medication Management Service for Chronic Obstructive Pulmonary Disease Patients in a Rural Health System

(13-386) Developing Ambulatory Pharmacy Transitions of Care Workflows to Support Primary Care Clinics

(13-388) Closing the Care Gap - Evaluating the Impact of Primary Care Clinical Pharmacists on the Management of Type 2 Diabetes and Chronic Kidney Disease

(13-389) Concurrent Use of Opioids and Benzodiazepines (COB): Evaluating Intervention Strategies to Reduce Prevalence in Outpatient Clinics

(13-390) Closing the Treatment Gap: Optimizing Migraine Care to Reduce ER Utilization

(1-095) Optimization of Guideline-Directed Medical Therapy Versus Standard of Care in Veterans Hospitalized with an Acute Heart Failure Exacerbation

(1-096) Evaluation of Prophylactic Anticoagulation usage within the Central Alabama Veterans Health Care System Inpatient setting

(1-097) Assessing Non-Receipt of Anticoagulation in High-Risk Patients with Atrial Fibrillation

(1-098) Bridging the Gap: Evaluation of Bridging Practices and Outcomes in Hospitalized Veterans on Chronic Anticoagulation Therapy

(1-099) Retrospective Review of Patients on Concomitant Direct Oral Anticoagulant (DOAC) and Antiplatelet and/or Nonsteroidal Anti-Inflammatory (NSAID) with Previously Dismissed Population Management Tool Interaction Flags

(1-100) Impact of a Pharmacist-Led Heart Failure Transition of Care Clinic on Optimization of Guideline-Directed Medical Therapy (GDMT) at James A Haley Veterans’ Hospital and Clinics

(1-101) Impact of Achieving Low-Density Lipoprotein Cholesterol Goal on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Veterans Post-Stroke

(1-102) Expanding Cardiology Pharmacists Role in Weight Management for Veterans with Heart Failure

(1-103) Optimization of Sodium-glucose Cotransporter-2 Inhibitors in Veterans with Heart Failure at the Carl Vinson VA Medical Center

(1-104) Enhancing Heart Failure Management for Veterans in a Pharmacist-Led Cardiology Clinic

(1-105) The Coprescription of Anticoagulants and Antiplatelets: An Analysis of Current Prescribing Trends at VA Maine Healthcare System

(1-106) Impact of Magnesium Sulfate Dosing on Clinical Outcomes in Emergency Department Patients with Atrial Fibrillation with Rapid Ventricular Response

(1-107) Integration of Pharmacist-Led Heart Failure Recommendations During Hospitalization

(1-108) Assessing the Safety and Appropriateness of Antiplatelet Medications in Patients on Oral Anticoagulants

(1-109) Medication Use Evaluation of the Dofetilide Ordering Process at the Harry S. Truman Memorial Veterans' Hospital

(1-110) Crow Service Unit Native Hearts Pilot Initiative to Improve Guideline-Directed Medical Therapy in American Indians/Alaska Natives with Heart Failure with Reduced Ejection Fraction

(1-111) Impact of Guideline-Directed Medical Therapy Optimization at Discharge on 90-Day Readmission Rates in Veterans with Heart Failure with Reduced Ejection Fraction

(1-112) Evaluation of Bleeding and Thromboembolism Rates with Rivaroxaban Use in an Elderly Veteran Population

(1-113) Assessing Utilization and Barriers to Guideline Directed Medical Therapy in Veterans with Heart Failure with Reduced Ejection Fraction

(1-114) Incidence of Stroke and VTE with Off-Label Dose Reduction of Apixaban for Atrial Fibrillation

(1-115) Evaluation Of Add-On Vericiguat On Hospitalizations In Veterans With Heart Failure With Reduced Ejection Fraction (HFrEF)

(1-116) Proprotein Convertase Subtilisin/Kexin Type 9 – Inhibitors Effect on LDL Lowering Over 3 Years

(1-117) Optimizing Direct-Acting Oral Anticoagulant Management Prior to Pain Procedures

(1-118) Concomitant Oral Anticoagulation and Aspirin: A Description of Current Co-Prescribing and Evaluation of Procedures at White City VA Medical Center

(1-119) Heart Failure Transitions of Care: The Impact of Pharmacists

(1-120) Evaluation of Tafamidis Prescribing and Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy at a Veterans Affairs Medical Center: A Quality Improvement Evaluation

(1-121) Outcomes of Anticoagulation Stewardship on Use of Concomitant Antiplatelets and Anticoagulants

(1-122) Comparative efficacy of sacubitril/valsartan doses on hospitalization for heart failure and mortality in a Veteran population

(1-123) Impact of a One-Time Dual Antithrombotic Review on Antiplatelet Deprescribing and Proton Pump Inhibitor (PPI) Initiation in a Veteran Population

(1-124) Use of potassium binders to optimize proteinuria therapy in patients with hypertension and chronic kidney disease

(2-106) Improving Outcomes in Heart Failure: A Retrospective Analysis of Intravenous Iron Therapy for Iron Deficiency

(2-145) Enhanced External Counterpulsation in Post-Stroke Care: A Systematic Review

(2-163) Heparin vs Bivalirudin in ECMO Patients: a Retrospective Comparison of Anticoagulation Outcomes

(2-202) Efficacy and harms of polypills for cardiovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials

(2-230) Beyond Blood Sugar: Comparing Blood Pressure Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Type 2 Diabetes

(2-261) The Impact of SGLT2 Inhibitors in Hospitalized Patients with Acute Decompensated Heart Failure

(2-267) Combined Roflumilast-Liraglutide Potently Suppress Adrenal Aldosterone Secretion Via Atrial Natriuretic Peptide

(2-272) The use of SGLT2 inhibitors in cardiovascular-kidney-metabolic syndrome

(2-276) Comparative Effectiveness of Metolazone Versus Chlorothiazide in Loop Diuretic-Resistant Acute Decompensated Heart Failure

(2-309) Factors Associated with Inappropriate Dosing of Direct Oral Anticoagulants Across Healthcare Settings: A Systematic Review of Real-World Evidence

(2-316) Heparin Monitoring After Oral Xa Inhibitor

(2-317) Factors Associated With Dose Selection and Adjustment of Direct Oral Anticoagulants in Chronic Kidney Disease: A Subanalysis Within Systematic Review

(2-322) Evaluating Intravenous Hydralazine Use in Hospitalized Patients at an Academic Medical Center

(2-337) Evaluation of Cardiovascular Risks of Gabapentinoids in Geriatric Populations: A TriNetX Comparative Outcomes Analysis

(2-342) Cognitive Impairment, Anticoagulation, and Clinical Outcomes in Older Adults with Atrial Fibrillation: Insights from the Systematic Assessment of Geriatric Elements in Atrial Fibrillation (SAGE-AF) Study

(2-376) Examining Thrombotic and Ischemic Events Following the Reversal of Direct Oral Anticoagulants in Medicare Patients

(3-037) Furoscix - Subcutaneous Furosemide for Outpatient Diuresis to Prevent Hospital Admission for Acute Decompensated Heart Failure

(3-042) Evaluating Early Initiation of Inpatient Therapeutic-dosing Anticoagulation after Acute Ischemic Stroke

(3-047) Comparing Bleeding Outcomes Between Ticagrelor and Prasugrel Following Percutaneous Coronary Intervention in Elderly Patients Receiving Dual Antiplatelet Therapy

(3-048) Comparison of Unfractionated Heparin Protocols in a Single Health Center

(3-060) Evaluation of Enoxaparin Dosing Strategies and Anti-Factor Xa-guided Adjustments for VTE prophylaxis in Trauma patients

(3-063) Striking the Balance: Single Versus Dual Antithrombotic Therapy Following Transcatheter Aortic Valve Implantation

(3-106) Evaluation of prescribing patterns of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction in an outpatient heart failure clinic

(3-126) Cardiotoxicity and Other Adverse Events Associated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Two-center Retrospective Study

(3-149) Evaluation of Balfaxar vs Kcentra for Warfarin Reversal at an Academic Medical Center

(3-153) Heart Failure Guideline-Directed Medical Therapy Optimization During a Hospitalization for Acute Decompensated Heart Failure

(3-165) Evaluation of Atrial Fibrillation Treatment Based on Patient Specific Factors

(3-180) High-Dose Thiamine for Post-Cardiothoracic Operation Vasoplegic Hypotension

(3-197) Investigation of the Anticoagulant Activity of 4-[5-(4-Carbamimidoylphenyl)furan-2-yl]benzenecarboximidamide

(3-233) Literature Evaluation of the Use of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction

(3-278) Evaluation and Optimization of International Normalized Ratio (INR) Goals in Patients with Mechanical Aortic Valves in a Pharmacist-Run Clinic: an Anticoagulation Stewardship Initiative

(3-297) Identifying the Anticoagulation Gap in Patients with Atrial Fibrillation

(3-305) Dual Antiplatelet Therapy as Secondary Prevention Following Non-Cardioembolic Ischemic Stroke: A single-center retrospective chart review

(3-307) An Inpatient Retrospective Evaluation of apixaban and rivaroxaban Loading Dose Strategies in the Setting of Acute Venous Thromboembolism

(3-309) The Role of As-Needed Loop Diuretics in Optimizing Heart Failure Management

(3-325) Safety and Efficacy of Direct Oral Anticoagulants Compared to Warfarin in Patients with Body Mass Index ≥ 40 kg/m2 In a Real-World Setting

(3-381) Evaluation of Cangrelor Transition Patterns to Oral P2Y12 Receptor Inhibitors

(4-011) Impact of an Anticoagulation Management Service-led Intervention on Rates of Antiplatelet and Gastric Bleeding Prophylaxis Use in Ambulatory Care Patients on Background Direct Oral Anticoagulants

(4-012) Improving Heart Failure with Reduced Ejection Fraction (HFrEF) Guideline Directed Medication Therapy (GDMT) Prescribed at Discharge Through Pharmacist Daily Review and Recommendations

(4-013) Evaluation of Comparative Coagulation Factor Strategies in the Management of Cardiac Surgical Bleeding

(4-014) Pharmacist -led Emergency Brilinta Delivery for Post MI Patients: A Systems Based Approach to Optimizing Antiplatelet Initiation

(5-001) Retrospective Evaluation of Reactions to Prophylactic Heparin Products in Patients with Documented Alpha-Gal Syndrome

(5-051) Impact of Pharmacists and Pharmacy Students on Evaluating Warfarin Patients for Appropriate Guideline-Directed Medical Therapy

(5-103) Comparative Analysis of Cardiac Myosin Inhibitors in the Treatment of Obstructive Hypertrophic Cardiomyopathy: Insights into the Safety & Efficacy of Phase III Clinical Trials

(5-140) Medication Use Evaluation of Rivaroxaban and Apixaban in Patients with Obesity in an Urban Academic Medical Center

(5-147) Gender Diversity in Coronary Heart Disease (CHD) Clinical Trials

(5-157) Retrospective Study on the Effect of In-Hospital Initiation of Empagliflozin on Readmission Rates in Patients with Heart Failure

(5-235) Implementation of a Pharmacist-Led Direct Oral Anticoagulant Management Service within a Community Hospital

(5-259) Perioperative Continuation Versus Discontinuation of SGLT2 Inhibitors and Clinical Outcomes in Trauma Surgery Patients

(5-295) Mechanisms and Management of Heparin Resistance: A Case Report

(5-305) Direct Oral Anticoagulant (DOAC) Hypersensitivity: Managing Cross-Reactivity Between Factor Xa Inhibitors

(5-331) Bleeding Rates of Apixaban versus Unfractionated Heparin in ICU Patients with Acute Kidney Injury

(6-014) Tolerability of Sodium-Glucose Linked Transporter 2 Inhibitors in Patients with a Left Ventricular Assist Device within a Community Health System

(6-036) Evaluation of a pharmacist-led guideline-directed medical therapy optimization program in hospitalized patients with heart failure

(6-044) Correlation of Lipoprotein(a) Levels and Heart Failure Outcomes

(6-051) Impact of Inclisiran on Low Density Lipoprotein Cholesterol Levels from Baseline: A Single Health System Retrospective Analysis

(6-052) Evaluation of CYP2C19 Genotype-Guided De-Escalation of P2Y12 Antiplatelet Agents in Patients After a Percutaneous Coronary Intervention in a Real-World Setting

(6-056) Evaluation of an inpatient pharmacy-to-dose enoxaparin protocol in obesity

(6-104) Assessment of Anticoagulation Use in Non-Valvular Atrial Fibrillation: A Multi-Clinic Quality Evaluation

(6-121) Comparison of Three Steroid Premedication Protocols for the Prevention of Iodinated Contrast Reactions

(6-122) Assessment of Antithrombotic Therapy Following Surgical Valve Replacement and Repair

(6-160) Clozapine-Induced Pericardial Syndromes: A Systematic Review of Case Reports

(6-165) Aminosalicylate-Induced Pericardial Syndromes: A Systematic Review of Case Reports

(6-166) Efficacy and Safety of Reduced Apixaban and Rivaroxaban Oral Lead-In Dosing After Receipt of Parenteral Anticoagulation: A Literature Review

(6-173) Perioperative Management of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Heart Failure Patients Without Diabetes

(6-186) Evaluation of Bivalirudin Protocol for VV ECMO

(6-196) Impact of weight-based dose-capping on time to therapeutic anticoagulation with intravenous heparin

(6-200) Evaluation of P2Y12 Loading Doses in Elective Stenting Patients

(6-205) The Safety of Early Initiation of Antithrombotic Therapy 8 Hours After Intravenous Thrombolysis for Acute Ischemic Stroke

(6-263) Impact of a Medication Optimization Clinic on Mortality for Patients with Heart Failure with Reduced Ejection Fraction and Mitral Regurgitation

(6-265) Impact of a Medication Optimization Clinic on Hospital Admissions for Patients with Heart Failure with Reduced Ejection Fraction and Mitral Regurgitation

(6-281) Evaluating Appropriateness of Antiplatelet Prescribing Among Patients Taking Warfarin in an Anticoagulation Clinic.

(6-315) Impact of Inpatient Pharmacist-Managed Warfarin on INR Trends

(6-333) Pharmacists role in attaining evinacumab for use in patients with persistent hypercholesterolemia

(6-337) Reassessing Andexanet Alfa: Evidence, Safety, and Cost Support 4F-PCC Utilization

(6-368) Anticoagulation in endocarditis

(7-027) Evaluation of Profilnine Use and Outcomes at an Academic Medical Center

(7-044) Case Report: Double Trouble: Solifenacin and Fluoxetine’s Unexpected QT Prolongation Synergy

(7-062) Intravenous Antiplatelets in Transition: Evaluating Eptifibatide and Cangrelor for Neurointerventional Radiology and Perioperative Bridging

(7-071) Assessment of Rosuvastatin Dosing in Patients with Renal Impairment Following Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting

(7-076) Evaluation of Indication and Duration of Dual Antiplatelet Therapy (DAPT) and Associated Clinical Events

(7-091) Impact of Obesity on Time to Therapeutic aPTTs in Patients Receiving Unfractionated Heparin for Venous Thromboembolism

(7-094) Evaluation of Heparin-Induced Thrombocytopenia (HIT) Antibody Testing and Associated Clinical Outcomes Based on 4T’s Scoring Criteria

(7-110) Characterization of Guideline-Directed Medical Therapy Utilization in Patients with Heart Failure with Reduced Ejection Fraction at an Academic Medical Center on the US-Mexico Border

(7-115) Dual Antiplatelet Therapy (DAPT) after Transient Ischemic Attack: Balancing Ischemic Prevention and Hemorrhagic Risk at Baylor Scott & White Medical Center- Temple

(7-120) Reducing Readmission Risk Through Guideline-Concordant Care in Atrial Fibrillation

(7-125) Evaluation of Impella Anticoagulation Strategies on Thromboembolic and Bleeding Complications

(7-126) Evaluation of Clinical and Safety Outcomes with Weight-Based Versus Fixed-Dose Four-Factor Prothrombin Complex Concentrate for the Reversal of Warfarin-Related Bleeding at an Academic County Health-System

(7-132) Evaluation of an Institutional Protocol for Anticoagulation Management After HeartMate 3 LVAD Implantation

(7-148) Management of Patients with Sickle Cell Disease (SCD) and Group 5 Pulmonary Hypertension (PH): A Systematic Review

(7-150) An Evaluation of the Efficacy and Safety of Anticoagulation Therapy in Peripartum Cardiomyopathy Patients: A Systematic Review

(7-168) Retrospective Evaluation of Inclisiran Efficacy on LDL-C Reduction in Patients Not at LDL-C Goal in a Cardiology Ambulatory Care Clinic

(7-182) Evaluation of Direct Oral Anticoagulant Renal Dosing Accuracy in Patients with Atrial Fibrillation at Hospital Discharge

(7-243) Identifying Areas for Pharmacist-led Interventions of Guideline-Directed Medical Therapy for Heart Failure in Hospitalized Adults

(7-267) Evaluating Predictors of Iron Goal Achievement and Long-Term Intravenous Iron Therapy Data in Patients with Heart failure or Pulmonary Hypertension

(7-312) Implementation of Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism

(7-313) Evaluating warfarin sensitivity post-cardiac valve replacement: a retrospective chart review

(8-015) Comparative Safety and Effectiveness of Antiplatelet Regimens After Transcatheter Aortic Valve Implantation in Patients with Coronary Artery Disease

(8-016) Health Outcomes of Guideline-directed Medical Therapy for Heart Failure in Patients with Transthyretin Amyloid Cardiomyopathy

(8-017) Prevalence and Predictors of Over-the-Counter Medication Use in Patients Hospitalized for Acute Heart Failure

(8-018) Utilization of Guideline-directed Medical Therapies for Hospitalized Patients with Heart Failure

(8-019) Relating Quantitative Measures of Guideline-Directed Medical Therapy to 30-Day Heart Failure Readmissions

(9-014) Evaluation of Revisions to Pharmacist-Directed Heparin Infusion Protocol

(9-025) Comparing Safety and Efficacy of Subcutaneous Unfractionated Heparin Dosing Frequencies for Venous Thromboembolism Prophylaxis in a Community Hospital

(9-058) Retrospective Evaluation of Two Types of Factor Products for Management of Perioperative Bleeding in Cardiac Surgery

(9-116) Fixed Versus Weight-Based Kcentra Dosing for Anticoagulation Reversal: A Pre-Post Implementation Study of Utilization, Effectiveness, and Safety

(9-145) Evaluation of Time to Therapeutic Activated Partial Thromboplastin Time (aPTT) in Patients Who Received Continuous Unfractionated Heparin After Target Range Changes in a Community Hospital

(9-149) Outcomes of Low-dose Four Factor Prothrombin Complex Concentrate in the Peri- and Post-operative Setting

(9-163) Evaluation of Optimized Post-Acute Coronary Syndrome Discharge Regimens on 90-Day Hospital Readmission

(9-231) Efficacy and Safety Evaluation of a Pharmacist- Driven Diuretic Protocol

(9-232) Clinical Impact on the Timing of Anticoagulation Switch in Patients with Documented Heparin-Induced Thrombocytopenia

(9-237) Achieving therapeutic IV heparin infusion using an alternative 15 units/kg/hour initial infusion protocol

(9-244) Evaluation of Intravenous Unfractionated Heparin Dosing in Obese Patients Using Anti-Xa Levels; A Multicenter, Retrospective Cohort Study

(9-250) Evaluation of Therapeutic Rivaroxaban Use in Peripheral Artery Disease Patients Following Lower Extremity Revascularization

(9-261) Comparing Provider-Driven and Pharmacist-Driven Warfarin Dosing Protocols in the Inpatient Setting Across a Health System

(9-266) Evaluation of Implementation of a Pharmacist Alert in the Electronic Medical Record for INR Change >0.5 in 24 Hours for Patients Receiving Warfarin

(9-294) Facilitating Length of Stay Reduction by Optimizing Anticoagulation Bridging Through Pharmacy-Led Transitions of Care Clinic

(9-298) Impact of Anticoagulation Strategies on Thrombotic Events in Patients with Durable Left Ventricular Assist Devices

(9-302) Evaluation of periprocedural antibiotic practices in high-risk patients undergoing cardiac implantable electronic device placement

(9-307) Evaluation of PRECISE-DAPT Score with Post-Discharge Gastrointestinal Bleeding (GIB) in Conary Artery Bypass Grafting (CABG) Patients Prescribed Dual Antiplatelet Therapy (DAPT)

(9-340) Evaluating Patient Selection for Inotropic Agents in Hospitalized Patients

(9-343) Predictors of a Successful Transition from Intravenous to Subcutaneous Insulin Post Open-Heart Surgery in Diabetic Patients

(9-344) Impact of Obesity on Time to Therapeutic Anticoagulation in Hospitalized Adults Receiving Heparin Infusions

(9-381) Direct Oral Anticoagulants and Potential Inconsistencies with Recommended Dosing in Atrial Fibrillation

(9-386) Comparing VTE Prophylaxis with Enoxaparin in Low Body Weight Patients with Renal Dysfunction vs Normal Renal Function

(9-387) Evaluation of Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Hospitalized Adults: A Pharmacist-Driven Retrospective Analysis

(9-388) Pharmacist-Led Anticoagulation Reconciliation at Hospital Discharge

(9-391) Evaluation of Dosing Limits on Weight Based Unfractionated Heparin Protocols

(9-413) Medication Use Evaluation of Diltiazem: Assessing Appropriateness and Ordering Practices at Manatee Memorial Hospital

(9-433) Four-Factor Prothrombin Concentrate Use in Heart Transplant: An Evaluation of Post-operative Thrombotic Complications

(9-435) Evaluation of Bleeding Risk Prediction by Comparing DOAC and HAS-BLED Scores in Patients on Oral Anticoagulation for Atrial Fibrillation

(9-437) Use of Bivalirudin Versus Argatroban Drip in Continuous Renal Replacement Therapy Patients

(9-461) Composite Bleeding Outcomes with Oral P2Y12 Inhibitors and Aspirin Post Percutaneous Coronary Intervention

(9-487) Heparin Monitoring Using Anti-Xa versus aPTT: A Retrospective Chart Review of Time to Therapeutic Anticoagulation

(9-498) DOAC Dashboards to Improve Inpatient Care: Pharmacy Resident Collaboration on Antithrombotic Stewardship

(10-002) Evaluation of Medication Prescribing at Discharge for Patients with Heart Failure Before and After Implementation of Pharmacist Involvement

(10-005) Safety and Efficacy of Antithrombin Administration at a Quaternary Pediatric Institution

(10-009) Outcomes with Full Versus Reduced Dose Rivaroxaban and Apixaban After Initial Venous Thromboembolism Treatment

(10-015) Evaluating Heparin Infusions and Resultant Monitoring Parameters

(10-029) Impact of a Pharmacist-Led Practice Change in Anti-Xa Monitoring on Bleeding Rates in Burn Injury Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis

(10-030) Evaluation of Vitamin K Antagonist versus Direct Oral Anticoagulants in the Management of Left Ventricular Thrombus

(10-058) A retrospective comparison of argatroban and heparin use in extracorporeal membrane oxygenation patients

(10-060) Impact of GLP-1 therapy on warfarin requirements in patients with a Left Ventricular Assist Device

(10-065) Fixed vs. Weight-based Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants in Patients with Intracranial Hemorrhage

(10-075) Pharmacist Led Warfarin Management Consults and Related Interventions in Community Hospital Setting

(10-098) Optimizing Enoxaparin Dosing: Outcomes of a Pharmacy Consult Protocol for High-Risk Populations

(10-102) Safety and Efficacy of Fixed Low-Dose Continuous Infusion Unfractionated Heparin Following Revascularization for Acute Limb Ischemia

(10-116) Evaluation of the Therapeutic Enoxaparin Anti-Xa Monitoring Guideline Utility within the OSF Ministry

(10-130) Evaluating the Compliance of a Nurse-Driven Unfractionated Heparin Infusion Protocol for the Treatment of Venous Thromboembolism

(10-133) Sodium-Glucose Cotransport 2 Inhibitors (SGLT-2i) and Heart failure: Impact on 30-day Readmission through a Pharmacist-Led Quality Improvement Initiative

(10-165) Comparing time to therapeutic activated partial thromboplastin level versus anti-Xa level in patients on intravenous unfractionated heparin.

(10-174) Evaluating the Prescribing Patterns of Antiplatelets After Acute Coronary Syndrome (ACS) at Community Health Network (CHNw)

(10-197) Comparison of Hypertension Outcomes in Pharmacist Managed Patients versus Cardiology Provider-Only Care Models

(10-203) Pharmacist-Driven Optimization of Guideline-Directed Medication Therapy (GDMT) in Heart Failure with Reduced Ejection Fraction (HFrEF)

(10-215) Incidence of Thromboembolic Events in Patients on Edoxaban with Estimated Creatinine Clearance > 95 mL/min

(10-216) Evaluation of Oral Anticoagulant Prescribing Practices in a Tertiary Care Academic Medical Center: A Retrospective Study

(10-225) Effectiveness and safety of Angiotensin receptor/neprilysin inhibitors compared with sodium-glucose cotransporter-2 inhibitors in patient with heart failure and reduced ejection fraction

(10-227) Evaluation of the Enoxaparin Use During Perioperative Warfarin Interruption at Mercy Anticoagulation Clinic

(10-231) Evaluation of Guideline-Directed Medical Therapy Prescribing and Optimization Practices for Admitted Patients with Heart Failure with Reduced Ejection Fraction

(10-236) Evaluation of Appropriate Guideline-Directed Medical Therapy Usage in Heart Failure with Reduced Ejection Fraction Upon Hospital Discharge

(10-238) Evaluation of Appropriate Guideline-Directed Medical Therapy Usage in Heart Failure with Preserved Ejection Fraction Upon Hospital Discharge

(10-241) Evaluating Guideline-Directed Medical Therapy Optimization in Patients with Heart Failure at an Ambulatory Clinic

(10-244) Safety and Efficacy of Direct Oral Anticoagulants (DOACs) in Patients with Obesity

(10-251) Effect of a Single Initial Therapeutic Anti-Xa Level on Patient Therapeutic Range during Heparin Therapy in a Community Hospital

(10-256) From Door to Discharge: Evaluating Pharmacist Involvement in ST-Segment Elevation Myocardial Infarction (STEMI) Patient Management at a Community Teaching Hospital

(10-290) Impact of a Risk-Assessment SmartPhrase on Diagnostic Evaluation for Cardiac Amyloidosis in a Heart Failure Clinic

(10-311) Impact of Pharmacist-Led Discharge Interventions on Patient Outcomes After Percutaneous Coronary Intervention (PCI)

(10-320) Evaluating the Appropriateness of Pharmacologic Venous Thromboembolism Prophylaxis in Hospitalized Patients with Class III Obesity: A Focus on Enoxaparin Dosing

(10-329) Assessing the appropriateness of chemical venous thromboembolism prophylaxis in hospitalized patients at a multi-campus community hospital

(10-331) Comparative Thrombotic Risk Following Administration of Andexanet Alfa Versus Four-Factor Prothrombin Complex Concentrate in Anticoagulant Reversal of Factor Xa Inhibitors

(10-357) Finding the Balance: Comparing Efficacy and Safety of Heparin Protocols in a Community Teaching Hospital

(10-373) Pharmacist-Led Discharge Reconciliation in Heart Failure: Effects on Readmission and Guideline-directed Medical Therapy Optimization

(10-377) Pharmacist-Managed Interventions to Reduce Inappropriate Antiplatelet Therapy in Hospitalized Patients

(10-398) Use of aPTT vs. anti-Xa for Therapeutic Heparin Monitoring

(10-400) Impact of Inpatient Pharmacist-led Intervention to Improve Guideline-Directed Medical Therapy Utilization at Discharge in Heart Failure Patients with Reduced Ejection Fraction

(10-404) Adherence to Institutional Direct Oral Anticoagulant to Parenteral Heparin Transition Protocol

(10-431) Impact of Baseline Monitoring on Outcomes After Intravenous Amiodarone Initiation

(10-450) The Impact of Pharmacist-Managed Discharge Medication Reconciliation and Access Coordination on Readmission Rate

(11-005) Comparison of Warfarin Management by Pharmacists and Non-Pharmacists on Time in Therapeutic Range in Hospitalized Patients

(11-027) Bye-Bye-Bivalirudin

(11-036) HIT or Miss: Evaluation of Testing and Management of Heparin-Induced Thrombocytopenia in Hospitalized Patients

(11-055) Evaluation of a Pharmacist-led Initial Direct Oral Anticoagulant Education within the Trinity Health Grand Rapids Anticoagulation Clinics

(11-074) Implementation of a Direct Oral Anticoagulant Discharge Program in a Community Hospital

(11-082) Deep Vein Thrombosis (DVT) Prophylaxis Strategies for Post Non-Hip or Non-Knee Orthopedic Surgeries

(11-086) Evaluation of P2Y12 Inhibitor Discontinuation in Patients After STEMI and Stent Placement

(11-105) Outcomes Associated with the Use of Beta-Blockers with Continuous Inotropes

(11-115) Evaluation of Congestive Heart Failure Patient Readmission Rate With Pharmacy Intervention

(11-118) Evaluation of the Effectiveness of Prothrombin Complex Concentrate (Human) for the Reversal of Direct Oral Anticoagulant-Associated Bleeding

(11-145) Warfarin Management With and Without Pharmacy Consult Services

(11-146) Comparative Evaluation of Intravenous Heparin Infusion Dosing in Obese Versus Non-Obese Patients

(11-148) Impact of Pharmacist Intervention and Cardiac Rehab in Post-Acute Myocardial Infarction Patients on 90-Day Readmission Rates

(11-149) Evaluation of Updated Enoxaparin Protocol for Venous Thromboembolism Prophylaxis in Trauma Patients

(11-153) Evaluation of Cost Savings for a Proposed Fixed Dose Regimen of Four-Factor Prothrombin Complex Concentrate Across a Health System

(11-162) Evaluation of Apixaban in Hemodialysis Patients Compared to Non-Hemodialysis Patients

(11-168) Comparative Dosing Strategies for Recombinant Factor Seven in Intraoperative and Postoperative Cardiothoracic Surgery

(11-184) Retrospective evaluation of GDMT optimization and readmission rates prior to pharmacy-led heart failure clinic

(11-195) Evaluation of Pharmacist-Managed Intravenous Iron Replacement in Patients Admitted for Heart Failure with Reduced Ejection Fraction

(11-229) Monitoring Unfractionated Heparin in Patients Transitioning from Factor Xa Inhibitors: A Quality Improvement Analysis Using Anti-Xa Levels

(11-235) Evaluation of Intravenous Heparin Weight-Based Versus Fixed Dosing Adjustments for the Treatment of Venous Thromboembolism or Atrial Fibrillation

(11-236) Venous Thromboembolism Prophylaxis in the Acute Burn Service

(11-253) Comparison of Metoprolol Succinate and Carvedilol and Implementing all 4 pillars of Guideline-Directed Medication Therapy (GDMT)

(11-269) Evaluation of Twice Daily Dosing of Enoxaparin for Venous Thromboembolism Prophylaxis in Obese Patients

(11-278) Facilitating automatic substitution therapy for venous thromboembolism (VTE) treatment in the Emergency Department (FAST-VTE)

(11-284) Time to Therapeutic IV Heparin in Patients with Acute Coronary Syndromes or Venous Thromboembolism

(11-295) Evaluating Unfractionated Heparin Management Using Activated Partial Thromboplastin Time at a Community Teaching Hospital

(11-298) Outcomes Associated with Anticoagulation in Cardiothoracic Surgery Patients with Post-Operative Thrombocytopenia

(11-299) Association of Loop Diuretic Optimization at Discharge with 30-day Readmission Rates in Acute Decompensated Heart Failure

(11-358) Improving the Rate of Follow-up Lipid Monitoring after Myocardial Infarction

(11-416) Evaluation of the Safety and Efficacy of Different Apixaban Lead-In Dosing Regimens in the Management of Acute Venous Thromboembolism

(11-433) Utilization of Alteplase vs Tenecteplase in the Setting of Acute Ischemic Stroke

(11-435) Incidence of Postoperative Atrial Fibrillation after Colchicine Use in Cardiac Surgery Patients

(11-439) Improving Anticoagulation Management: Retrospective Identification and Prospective Transition of Eligible Inpatients from Warfarin to Direct Oral Anticoagulants

(11-448) Frequency of Inappropriate Direct Oral Anticoagulant Dose Reductions among Hospitalized Adults

(11-455) Evaluation of anticoagulation therapy in patients with suspected heparin-induced thrombocytopenia in a community-teaching hospital

(11-457) Evaluation of Team-Based Care Versus Usual Care on Heart Failure Patient Outcomes

(11-466) Assessment of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol in Major Hemorrhage Through Redosing and Hemostatic Response

(11-467) Comparison of Activated Partial Thromboplastin Time (aPTT) Effect Between Two Four-Factor Prothrombin Complex Concentrate (4F-PCC) Formulations in Patients on Apixaban

(11-471) Comparing length of argatroban use amongst patients managed with warfarin versus a direct oral anticoagulant (DOAC) for the treatment of heparin-induced thrombocytopenia

(12-016) Evaluation of Intravenous Cangrelor for Neuroendovascular Procedures at a Large Academic Medical Center

(12-035) Diltiazem and Low Ejection Fraction

(12-054) Evaluation of a Treatment-Dose Enoxaparin Protocol in Patients with Obesity

(12-058) Prescribing and Monitoring Patterns of Oral Sotalol Initiation in a Multi-Center Health System

(12-085) Direct Oral Anticoagulant and Heparin Anti-Xa Interference Pharmacist Workflow Use Evaluation

(12-086) The Impact of Direct Oral Anticoagulant Timing on Bleeding Events Post-Ischemic Stroke

(12-113) Does Obesity Affect Coagulopathy on Factor Xa Inhibitors? (DOAC FAX )

(12-116) Assessment of Inpatient Utilization and Prescribing Trends of Sacubitril/Valsartan in a Hospital Setting

(12-141) Comparison of aPTT versus Anti-Xa Monitoring Protocols for Unfractionated Heparin in a Community Hospital: A Retrospective Analysis

(12-142) Comparing Clinical Outcomes Between Watchman and AtriClip Devices Following Device Implantation

(12-143) Pharmacy-Led CHF Education and Impact on Readmission Rates

(12-173) Systemic Argatroban vs Heparin in Patients with Microaxial Flow Pumps​

(12-174) Evaluation of Timing of Direct Oral Anticoagulants Before Direct Current Cardioversion

(12-178) Comparison of 4-Factor PCC and Recombinant Factor VIIa for Perioperative Coagulopathy Management in Cardiac Surgery

(12-185) Frequency of Normal Sinus Rhythm: Intravenous Metoprolol Compared to Intravenous Digoxin

(12-187) The Effect of Renal Function on Ventricular Arrhythmia-Free Days for Cardiogenic Shock Patients Receiving Dobutamine or Milrinone

(12-202) Comparison of Non-Weight-Based vs Weight-Based Heparin Infusion Dosing Protocol at a Community Hospital

(12-225) Evaluating the Maximum Initial Bolus and Infusion Rate of Heparin for Acute Coronary Syndrome in Patients Weighing Greater Than or Equal to 90 Kg

(12-263) Efficacy and Safety of Bivalirudin in Patients on Extracorporeal Membrane Oxygenation (ECMO)

(12-264) Management of Mechanical Heart Valve Subtherapeutic INRs for Patients on Warfarin Therapy in a Pharmacist-Led Anticoagulation Clinic

(12-275) Evaluation of Argatroban Dosing and the Time of Discontinuation After a Negative Heparin Induced Thrombocytopenia (HIT) Panel

(12-276) Evaluating the appropriateness of IV unfractionated heparin dosing in obese patients

(12-279) Evaluating Appropriateness and Pharmacist Involvement of Inpatient Warfarin Bridging

(12-282) Evaluation of Iron Deficiency Screening Rates for Patients Newly Diagnosed with Heart Failure

(12-284) Evaluation of Subcutaneous Furosemide use in Ambulatory Patients with Heart Failure

(12-285) Evaluation of Warfarin Versus Direct Oral Anticoagulant Use Among Primary Care Patients with Venous Thromboembolism

(12-290) Appropriate Use and Cost Assessment of Isoproterenol in Atrioventricular Block

(12-340) Assessing Inpatient Pharmacist Role in Optimizing Sodium-Glucose Cotransporter-2 Inhibitor (SGLT-2 Inhibitor) Use in Patients with Heart Failure Prior to Discharge

(12-342) Pharmacist intervention to optimize guideline-directed medication therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF)

(12-343) Use of Bicarbonate Based Purge Solution Versus Heparin Based Purge Solution in Patients with an Impella Post-Cardiotomy

(12-351) Gastroprotection with Proton Pump Inhibitors for Patients on Dual Antiplatelet Therapy after Acute Coronary Syndrome

(12-356) Evaluating the Appropriateness of Venous Thromboembolism Prophylaxis in Hospitalized Patients

(12-364) Assessment of the Role of Potassium Binders in Heart Failure Patients on Guideline Directed Medical Therapy

(12-377) Evaluation of heparin dosing in obesity for treatment of deep vein thrombosis and pulmonary embolism.

(12-406) Evaluation of P2Y12 inhibitor dispensing to patients with new coronary stents prior to discharge

(12-409) Evaluation of Vutrisiran in ATTR Amyloidosis with Cardiomyopathy

(12-410) Evaluation of empagliflozin and dapagliflozin use at Prisma Health

(12-417) Anticoagulation management in patients requiring intra-aortic balloon pumps

(12-419) Assessing current perioperative planning processes and outcomes for patients on anticoagulation

(12-424) Utilization of Heart Failure Guideline-Directed Medical Therapy at a Rural Community Hospital

(13-007) Assessment of Heparin Infusion Protocol in Obese Patients

(13-010) Impact of continuous versus intermittent loop diuretics for acute decompensated heart failure on hospital length of stay

(13-041) Evaluation of Pharmacist Discharge Counseling in Heart Failure Patients

(13-047) Sotalol Dose Adjustments in Obese vs. Non-Obese Patients

(13-066) Incidence Rate and Trends of Hospital Acquired Anemia in Non-Surgical Patients Receiving Therapeutic Anticoagulation vs Venous Thromboembolism Prophylactic Anticoagulation

(13-069) Assessing the Real-World Impact of Inclisiran on Clinical Outcomes in an Outpatient Cardiology Clinic

(13-089) Evaluating the Impact of a Cardiology-Focused Unit on Guideline Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction at Hospital Discharge

(13-095) Use and Safety of Direct Oral Anticoagulants Immediately Following Bioprosthetic Valve Replacement in Patients with Atrial Fibrillation

(13-111) Off-Label Reduced Dosing of DOACs: Are We Harming or Helping?

(13-119) The Evaluation of Anti-Xa Ordering Practices and Heparin Order Set Adherence at a Texas Academic Medical Center

(13-124) Comparison of the Positive Predictive Value of ELISA vs LIA in the Diagnosis of Heparin-Induced Thrombocytopenia

(13-130) Incidence of VTE and Bleeding Outcomes in Heart Transplant Recipients at a Large Academic Medical Center

(13-158) Impact of AV Nodal Blockers on Incidence of Heart Block and Permanent Pacemaker pre and post Transcatheter Aortic Valve Implantation: The BLOCK-TAVI Study

(13-160) Medication Use Evaluation of Entresto in an Inpatient Setting

(13-161) Medication Use Evaluation of Apixaban in a South Texas Academic Institution

(13-163) Medication Use Evaluation of Tenecteplase: A Guide to Superior Patient Outcome

(13-166) Medication Use Evaluation of Sotalol: Optimizing Safe Use at Harris Health

(13-180) Evaluating the Impact of Pharmacist-led Discharge Education and Bedside Medication Provision on Readmission Rates in Myocardial Infarction Patients Receiving Dual Antiplatelet Therapy

(13-182) Examining the Influence of Guideline-Directed Medical Therapy on 30-Day Readmission Rates in Patients with Heart Failure with Reduced Ejection Fraction

(13-203) Prescribing Patterns and Clinical Outcomes of Parenteral Anticoagulant to Direct Oral Anticoagulant Transitions

(13-217) Exploring Opportunities for Pharmacists Involvement in Post-Discharge Anticoagulation Care

(13-225) Impact of Weight-Based Dosing Strategies on Heparin Therapy Outcomes in Patients with Elevated BMI

(13-227) Effect of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) on the Incidence of Acute Kidney Injury in Patients Hospitalized with Acute Decompensated Heart Failure

(13-231) Evaluation of Guideline-Directed Medication Therapy Initiation in Patients with Newly Diagnosed Heart Failure with Reduced Ejection Fraction in the Inpatient Setting

(13-233) Incidence of Cardiogenic Shock Following Administration of Intravenous Diltiazem for Acute Management of Atrial Fibrillation/Flutter with Rapid Ventricular Response in a Community Hospital Setting

(13-242) Identifying Opportunities to Optimize Guideline-Directed Medical Therapy in Heart Failure to Reduce Readmissions

(13-247) Safety and Efficacy of Colchicine for Prevention of Post-Operative Atrial Fibrillation after Cardiothoracic Surgery

(13-284) Pharmacist Outreach and Support during Transitions of Care for Heart Failure (The POST-HF Trial)

(13-310) Development of a Comprehensive VTE Management Protocol to Optimize Dosing of Low Molecular Weight Heparin (LMWH) in the Inpatient Setting

(13-320) Therapeutic Heparin Ordering Practices for Atrial Fibrillation - Full dose vs. Cardiac dose

(13-333) A Medication Use Evaluation of Therapeutic Enoxaparin in the Cardiac Intensive Care Unit at a Free-Standing Children’s Hospital

(13-347) The Association of Area Deprivation Index and Oral Anticoagulants Adherence Rates in Community Pharmacy Patients

(13-350) Comparing 30-Day Readmission Rates with Varying Diuresis Strategies in Heart Failure Exacerbation

(13-354) Magnesium Boluses for Post Operative Atrial Fibrillation Prevention

(13-399) Implementation of recommendation tool for IV iron in HFrEF